




>>Entry Name: **Gadoteridol**, BAN, INN, USAN

Synonym(s): [10-(2-Hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)- $N^1, N^4, N^7, N^{10}, O^1, O^4, O^7, O^{10}$]gadolinium, 12Cl. [1,4,7-Tris(carboxymethyl)-10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecanato(3-)]gadolinium. **Gd(HP-D03A)** $\ddagger$. ProHance. SQ 32692



CAS Registry Number: 120066-54-8

Molecular Formula: $C_{17}H_{29}GdN_4O_7$

Molecular Weight: 558.689

Accurate Mass: 559.127725

Percentage Composition: C 36.55%; H 5.23%; Gd 28.15%; N 10.03%; O 20.05%

Source/Synthesis: Synth. from Gd_2O_3 and the ligand in deionized H_2O at 95° for 20h

Use/Importance: Non-ionic contrast agent for magnetic resonance imaging (for e.g. CNS tumours)

Physical Description: White solid + 0.31 H_2O (MeOH/Me $_2$ CO)

Melting Point: Mp 225°

Solubility: Sol. H_2O

Hazard & Toxicity: LD $_{50}$ (mus, ivn) 6146 mg/kg

>>Derivative: Aqua complex

see Aqua[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato]gadolinium, [MWG35-P](#)

References:

- Eur. Pat.*, 1988, *ER Squibb*, 292 689; *CA*, **110**, 173270f, (synth, use)
Dischino, D.D. *et al.*, *Inorg. Chem.*, 1991, **30**, 1265, (synth, fab-ms, ir)
Invest. Radiol., Suppl. 1, 1992, **27**, S1, (rev)
Yuh, W.T. *et al.*, *Invest. Radiol., Suppl. 1*, 1992, **27**, S39
Drugs of Today (Barcelona), 1993, **29**, 311, (rev)
Runge, V.M. *et al.*, *J. Magn. Reson. Imaging*, 1994, **4**, 669, (use)